Is retroelement-based gene editing a safer alternative to CRISPR-Cas approaches?

In a Perspective, Stephen Tang and Samuel Sternberg discuss retroelement-based gene editing as a safer alternative to CRISPR-Cas approaches.

Lexicon to face FDA AdComm for Zynquista approval in diabetes and CKD

In 2019, the FDA declined to approve Lexicon’s Zynquista as an adjunct to insulin in type 1 diabetes, citing safety concerns following a split 8-8

August 22, 2024

Pharma companies delist patents from FDA’s Orange Book following FTC challenges

At least three pharma companies have requested to pull patents from an FDA database after the Federal Trade Commission challenged more than 100 patents it

December 22, 2023

Case Western Reserve University receives grant to investigate AML treatment for veterans

With a new four-year, $1.3 million grant from the U.S. Department of Veterans Affairs, researchers at Case Western Reserve University are investigating a new approach

October 15, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.